Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albumin gel-platelet-rich fibrin (ALB-PRF) is an autologous blood-derived biomaterial created through a two-stage process: heating of serum and low platelet plasma to form an albumin gel, followed by incorporation of cells and growth factors from liquid PRF. This creates a biphasic, highly cellularized material that provides slow and gradual release of growth factors over extended periods, with significantly longer degradation time than traditional PRF. It demonstrates enhanced biocompatibility, reduced inflammatory response, and improved regenerative properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on albumin gel-platelet-rich fibrin.